Pacific Biosciences of California (Pacific Biosciences of California) Risk Assessment

View and export this data going back to 2010. Start your Free Trial

What is Pacific Biosciences of California Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Pacific Biosciences of California is: High Risk: High uncertainty.

Competitive Comparison of Pacific Biosciences of California's Risk Assessment

For the Medical Devices subindustry, Pacific Biosciences of California's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacific Biosciences of California's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's Risk Assessment falls into.

Pacific Biosciences of California (NAS:PACB) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Pacific Biosciences of California Risk Assessment Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Biosciences of California (Pacific Biosciences of California) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (NAS:PACB) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

P09:Germany P09:Germany

Address

1305 O’Brien Drive, Menlo Park, CA, USA, 94025

Website

https://www.pacb.com

Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.

Executives

Oene Mark Van	officer: Chief Operating Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Christian O Henry	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
David W Meline	director	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Susan G. Kim	officer: Chief Financial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Jeff Eidel	officer: See Remarks	1305 O'BRIEN DR., MENLO PARK CA 94025
Michele Farmer	officer: Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
William W. Ericson	director	777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
Peter Fromen	officer: Chief Commercial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michael Hunkapiller	director	400 HAMILTON AVENUE, 4TH FLOOR, PALO ALTO CA 94301
Eric Schaefer	officer: VP Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Kathy Ordonez	director	3 GIRALDA FARMS, C/O QUEST DIAGNOSTICS, MADISON NJ 07940
Randall S Livingston	director
Lucy Shapiro	director	10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
David Botstein	director	1380 WILLOW ROAD, PACIFIC BIOSCIENCES OF CALIFORNIA INC, MENLO PARK CA 94025